The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
New research highlights how the brain's reward-learning system can guide personalized treatments for depression.
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Encephalitis survivors experience hidden mental health struggles and there is an urgent need for improved support within the ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...